These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26072957)

  • 1. Bilosomes: A Novel Approach to Meet the Challenges in Oral Immunization.
    Chauhan MK; Sahoo PK; Rawat AS; Singh A; Bamrara A; Sharma D
    Recent Pat Drug Deliv Formul; 2015; 9(3):201-12. PubMed ID: 26072957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines.
    Aburahma MH
    Drug Deliv; 2016 Jul; 23(6):1847-67. PubMed ID: 25390191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes).
    Shukla A; Khatri K; Gupta PN; Goyal AK; Mehta A; Vyas SP
    J Pharm Pharm Sci; 2008; 11(1):59-66. PubMed ID: 18445364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam.
    Al-Mahallawi AM; Abdelbary AA; Aburahma MH
    Int J Pharm; 2015 May; 485(1-2):329-40. PubMed ID: 25796122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bile Salt Stabilized Vesicles (Bilosomes): A Novel Nano-Pharmaceutical Design for Oral Delivery of Proteins and Peptides.
    Ahmad J; Singhal M; Amin S; Rizwanullah M; Akhter S; Kamal MA; Haider N; Midoux P; Pichon C
    Curr Pharm Des; 2017; 23(11):1575-1588. PubMed ID: 28120725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilosomes in the context of oral immunization: development, challenges and opportunities.
    Shukla A; Mishra V; Kesharwani P
    Drug Discov Today; 2016 Jun; 21(6):888-99. PubMed ID: 27038539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral mucosal immunization using glucomannosylated bilosomes.
    Jain S; Indulkar A; Harde H; Agrawal AK
    J Biomed Nanotechnol; 2014 Jun; 10(6):932-47. PubMed ID: 24749389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes.
    Shukla A; Katare OP; Singh B; Vyas SP
    Int J Pharm; 2010 Jan; 385(1-2):47-52. PubMed ID: 19835938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate.
    Elnaggar YSR; Omran S; Hazzah HA; Abdallah OY
    Int J Pharm; 2019 Jun; 564():410-425. PubMed ID: 31029657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization.
    Singh P; Prabakaran D; Jain S; Mishra V; Jaganathan KS; Vyas SP
    Int J Pharm; 2004 Jul; 278(2):379-90. PubMed ID: 15196642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes.
    Mohsen AM; Asfour MH; Salama AAA
    Drug Dev Ind Pharm; 2017 Dec; 43(12):2043-2054. PubMed ID: 28756693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bilosomes as a novel carrier for the cutaneous delivery for dapsone as a potential treatment of acne: preparation, characterization and
    El-Nabarawi MA; Shamma RN; Farouk F; Nasralla SM
    J Liposome Res; 2020 Mar; 30(1):1-11. PubMed ID: 31010357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats.
    Ahad A; Raish M; Ahmad A; Al-Jenoobi FI; Al-Mohizea AM
    Eur J Pharm Sci; 2018 Jan; 111():409-417. PubMed ID: 29030177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentials of human bile acids and their salts in pharmaceutical nano delivery and formulations adjuvants.
    Kecman S; Škrbić R; Badnjevic Cengic A; Mooranian A; Al-Salami H; Mikov M; Golocorbin-Kon S
    Technol Health Care; 2020; 28(3):325-335. PubMed ID: 31594273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the Potential of Bilosomes and Modified Bilosomes: a Comprehensive Journey into Advanced Drug Delivery Trends.
    Nayak D; Rathnanand M; Tippavajhala VK
    AAPS PharmSciTech; 2023 Nov; 24(8):238. PubMed ID: 37989979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes).
    Conacher M; Alexander J; Brewer JM
    Vaccine; 2001 Apr; 19(20-22):2965-74. PubMed ID: 11282208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Vesicular Bilosomal Delivery Systems for Dermal/Transdermal Applications.
    Suvarna V; Mallya R; Deshmukh K; Sawant B; Khan TA; Omri A
    Curr Drug Deliv; 2024; 21(7):961-977. PubMed ID: 37424346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge.
    Arzani G; Haeri A; Daeihamed M; Bakhtiari-Kaboutaraki H; Dadashzadeh S
    Int J Nanomedicine; 2015; 10():4797-813. PubMed ID: 26251598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanosized Liposomes Containing Bile Salt: A Vesicular Nanocarrier for Enhancing Oral Bioavailability of BCS Class III Drug.
    Arafat M; Kirchhoefer C; Mikov M; Sarfraz M; Löbenberg R
    J Pharm Pharm Sci; 2017; 20(0):305-318. PubMed ID: 28885915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of bilosomes as nanocarriers for transdermal delivery of tizanidine hydrochloride: in vitro and ex vivo optimization.
    Khalil RM; Abdelbary A; Kocova El-Arini S; Basha M; El-Hashemy HA
    J Liposome Res; 2019 Jun; 29(2):171-182. PubMed ID: 30221568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.